Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of Beigene stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96.
Beigene Trading Up 3.2 %
ONC stock traded up $7.51 during midday trading on Thursday, reaching $244.20. 758,979 shares of the company’s stock traded hands, compared to its average volume of 354,999. The stock has a market cap of $23.90 billion, a price-to-earnings ratio of -29.64, a price-to-earnings-growth ratio of 9.50 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16.
About Beigene
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Articles
- Five stocks we like better than Beigene
- Why Invest in High-Yield Dividend Stocks?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What Are Trending Stocks? Trending Stocks Explained
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Stock Market Sectors: What Are They and How Many Are There?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
